M+QuickMedCalc
Educational reference only. Not a diagnostic tool. See full disclaimer.
CardiologyNon-HDL-C

Non-HDL Cholesterol Calculator

Calculate non-HDL cholesterol from total cholesterol minus HDL-C from the same lipid panel, with unit-safe arithmetic and guideline-context limitations.

Content updated: View sources

QuickMedCalc is developed and maintained by an independent developer. Medical content is not independently reviewed by a physician.

Formula and medical content are based on the references listed on this page. See sources, About, and Sources and Review Process.

Model identity: calculate total cholesterol minus HDL-C from the same lipid panel and clinical time point. Non-HDL-C is the part of total cholesterol not counted as HDL-C; it is not a directly measured single “bad cholesterol,” apoB, particle number, or an ASCVD risk percentage. This page never selects a treatment goal.

Use the single unit printed for total cholesterol and HDL-C on the same lipid panel. The first or unchanged selection preserves entered values; a different unit or clearing the unit clears them.

Use total cholesterol from the same lipid panel and clinical time point in the selected unit. This technical display limit is not a healthy or clinical reference range.

Use HDL-C from the same lipid panel and clinical time point in the selected unit. HDL-C can be zero for arithmetic; this is not a reference-range statement.

About

Non-HDL-C is the derived cholesterol concentration obtained by subtracting HDL-C from total cholesterol. Use total cholesterol and HDL-C from the same lipid panel, clinical time point, and unit. The result is aggregate cholesterol mass, not a direct measurement of one lipoprotein, particle number, ASCVD risk, treatment target, or treatment selector.[3, 5]

Current guideline and laboratory guidance include non-HDL-C in the standard lipid-profile report because it summarizes cholesterol carried by non-HDL lipoproteins. That reporting role does not make it an ApoB count or a substitute for the rest of a lipid assessment.[1, 2, 3]

In appropriate sample contexts the aggregate can include cholesterol in LDL, IDL, VLDL, remnant lipoproteins, Lp(a), and, especially after a meal, chylomicron or chylomicron-remnant particles. It cannot separately identify or quantify those components, isolate Lp(a)-C, or diagnose an abnormal particle such as LpX. ApoB, LDL particle number, LDL-C, and remnant-cholesterol definitions answer different questions.[3, 7, 9]

Routine lipid profiles may be fasting or nonfasting. The subtraction has no triglyceride input, but feeding, high triglycerides, inherited lipid disorders, and special clinical pathways can change sample interpretation or whether a repeat fasting specimen is useful. This page does not collect fasting status or decide a repeat test.[3, 6]

The 2026 guideline examples below are static context only. This page does not calculate PREVENT or ASCVD risk, determine risk group or guideline pathway, or choose a personal goal, and it does not compare a submitted result with those examples. [1, 2]

Formula

Non-HDL-C = total cholesterol − HDL-C. Use same-panel values in the same selected unit; this is a derived cholesterol concentration, not a particle count or risk score. [3, 5]
Example arithmetic: 200 mg/dL − 50 mg/dL = 150 mg/dL; 5.2 mmol/L − 1.3 mmol/L = 3.90 mmol/L. Internal subtraction is not a guideline comparison.[7]
TC = HDL-C is a valid zero result; HDL-C > TC is rejected rather than silently corrected. No triglyceride, LDL-C, ApoB, remnant, PREVENT, target, or treatment calculation runs here.

Interpretation

What non-HDL-C can contain

Static composition context; the runtime cannot separate these components.
ComponentHow it relatesCalculated separately here?
LDL and IDLAtherogenic lipoprotein cholesterol can contribute to the aggregate.No
VLDL and remnant lipoproteinsVLDL/remnant cholesterol can contribute, especially as triglyceride-rich particles change.No
Lipoprotein(a)Lp(a)-cholesterol can be part of non-HDL-C, but its contribution is not isolated.No
Chylomicron and chylomicron remnantsThese may contribute in appropriate nonfasting or high-triglyceride contexts.No
LpX or abnormal particlesUnusual particles may affect interpretation; this calculator does not diagnose them.No

Non-HDL-C is aggregate cholesterol mass. It cannot identify, quantify, or convert one component into another. [3, 4]

Non-HDL-C compared with other measurements

Different quantities are not interchangeable.
MeasurementWhat it representsThis page
Non-HDL-CTC − HDL-C; aggregate cholesterol massOnly runtime output
LDL-CLDL cholesterol concentration from calculation or measurementNot calculated
ApoBParticle-number-related apolipoprotein measurementNot calculated
Remnant cholesterolA research/clinical definition dependent on TC, HDL-C, and LDL-C methodNot calculated
LDL particle numberAdvanced particle measureNot calculated
Lp(a)Independent lipoprotein whose cholesterol can contribute to the aggregateNot measured or converted

High correlation does not make ApoB and non-HDL-C the same variable. Cholesterol mass per particle varies, and discordance can matter with high triglycerides, diabetes, low LDL-C, or treatment states. [5, 7, 8]

Fasting and static 2026 guideline examples

Fasting is not routinely required for every lipid profile, but feeding can change some lipids and special pathways may call for a fasting repeat. This page neither collects fasting status nor decides whether repeat testing is needed. [3, 6]

Selected 2026 examples; not a normal range, exhaustive table, or result classifier.
Guideline contextStatic example
Borderline/intermediate primary prevention after guideline-selected therapy<130 mg/dL (~<3.4 mmol/L)
High-risk primary prevention after full PREVENT assessment<100 mg/dL (~<2.6 mmol/L)
Very-high-risk secondary prevention<85 mg/dL (~<2.2 mmol/L)

These are static guideline examples, not normal/abnormal labels or an instruction to compare a submitted result. The page does not determine risk group, PREVENT category, or treatment goal. [1, 2]

Special contexts and zero arithmetic

Pregnancy, pediatric assessment, acute illness, diabetes, CKD, familial hypercholesterolemia, severe triglycerides, chylomicronemia, type III dysbetalipoproteinemia, cholestatic disease/LpX, changing therapy, and abnormal HDL can require a different clinical or laboratory pathway. This page has no special algorithm and does not diagnose or choose treatment.

A TC = HDL-C result of zero is valid arithmetic; it does not prove absence of atherogenic particles or health. HDL-C above total cholesterol fails validation rather than being auto-corrected.

What this calculator computes

It reads two same-panel concentrations, checks the selected unit, subtracts HDL-C from total cholesterol at full precision, and displays the derived non-HDL-C concentration. It does not read triglycerides, LDL-C, ApoB, particle number, Lp(a), fasting status, risk history, or treatment information. The worked arithmetic 200 − 50 = 150 mg/dL is not a personal goal or risk estimate.

Why methods and discordance matter

Non-HDL-C, LDL-C, ApoB, remnant cholesterol, LDL particle number, and Lp(a) use different quantities or methods. A strong population correlation does not establish individual equivalence; particle cholesterol content can vary, so discordance is a context for clinical interpretation rather than a value this page can resolve. [5, 7, 8]

What this page cannot determine

It cannot diagnose dyslipidemia, estimate cardiovascular or ASCVD risk, assign a PREVENT category, identify a lipoprotein disorder, choose a treatment goal, recommend medication or testing, or decide whether a fasting repeat is needed. Those questions require the complete clinical and laboratory context.

References

  1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026;153:e1154–e1276. PMID 41824552. DOI 10.1161/CIR.0000000000001423.
  2. Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. 2026. PMID 42330109. DOI 10.1161/CIR.0000000000001457.
  3. Cao J, Donato L, El-Khoury JM, et al. ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins. J Appl Lab Med. 2024;9(5):1040–1056. PMID 39225455. DOI 10.1093/jalm/jfae057.
  4. Correction to: ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins. J Appl Lab Med. 2025. PMID 40172951. DOI 10.1093/jalm/jfaf021.
  5. Langlois MR, Nordestgaard BG, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med. 2020;58(4):496–517. PMID 31855562. DOI 10.1515/cclm-2019-1253.
  6. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile. Eur Heart J. 2016;37:1944–1958. PMID 27122601. PMCID PMC4929379. DOI 10.1093/eurheartj/ehw152.
  7. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of LDL-C, non-HDL-C, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337–345. PMID 21487090. DOI 10.1161/CIRCOUTCOMES.110.959247.
  8. Sniderman AD, Dufresne L, Pencina KM, et al. Discordance Among ApoB, Non–High-Density Lipoprotein Cholesterol, and Triglycerides: Implications for Cardiovascular Prevention. Eur Heart J. 2024. PMID 38700053. PMCID PMC11242442. DOI 10.1093/eurheartj/ehae258.
  9. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326–333. PMID 16030277. DOI 10.1001/jama.294.3.326.

FAQ

Related Calculators

Disclaimer

Educational and informational reference only. Not intended to replace professional medical advice, diagnosis, treatment, or independent verification.